

Velkommen til


# Tverrfaglig nasjonalt møte om lungekreft

4. mai 2018






# Nasjonalt...



## Tverrfaglig...



Variasjon





Ønsket variasjon

Ubetydelig variasjon

Uønsket variasjon

Person-tilpasning  
Optimalisering

Ulike tradisjoner  
Tilfeldigheter


Ulike tidsforløp?  
Ulik tilgang til kliniske studier?  
Ulik tilgang til avanserte teknikker/behandling?  
Ulik kapasitet?  
Ulik kvalitet?




Noen trender

2018


## Antall nye lungekrefttilfeller pr år, 2000-2016



## Median overlevelse, 2000-2016




## 1- og 5-årsoverlevelse, 2000-2016




Krefregisteret, "periodetilnærming"

## Lungekreft-prevalens 2000-2016




## Forbedret prognose hos ikke-opererte i tidlig stadium ("lokalisert sykdom")


Non-operated females




Non-operated males



Operated females




Operated males




«Stereotaksi» kan vere eit alternativ til kirurgi



# Tilpassa inn mot ømfintlege strukturar



# Behandling av tidleg-stadium lungekreft



Medisinsk  
behandling



# What's hot



The NEW ENGLAND  
JOURNAL of MEDICINE

SPECIALTIES TOPICS MULTIMEDIA CURRENT ISSUE LEARNING AUTHOR CENTER

ORIGINAL ARTICLE  
MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

## Addition of Immunotherapy in Lung Cancer

L. Gandhi and Others

The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival than chemotherapy alone. Immune-related adverse effects were more common with the combination.

FREE

APR 16

ORIGINAL ARTICLE  
MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

## Tumor Mutational Burden and Immunotherapy in Lung Cancer

M.D. Hellmann and Others

Among patients with non-small-cell lung cancer and tumors containing at least 10 mutations per megabase, the 1-year progression-free survival rate was 43% with pembrolizumab plus ipilimumab versus 13% with chemotherapy. This result was independent of PD-L1 expression level.

FREE


APR 16

PERSPECTIVE

## Aligning Efforts in Global Health

R.S. Dhillon and A. Karan

Should we pursue global health initiatives to ensure health security, promote development, or achieve health equity as a human right? Perhaps we can delineate actionable issues incorporating key



ORIGINAL ARTICLE  
MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

## Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

P.M. Forde and Others

In a pilot study, two doses of neoadjuvant nivolumab administered to patients with resectable lung cancer resulted in a major pathological response in 45% and amplified T-cell clones specific for tumor antigens.

FREE

APR 16

CORRESPONDENCE

## Breakthrough-Therapy Designation

J. Corrigan-Curay, A.E. McKee, and P. Stein

The authors provide a perspective on the rationale and goals of the designation of "breakthrough therapy" by the Food and Drug Administration.



### Image Challenge

What is the diagnosis?  
[Answer »](#)

### Image of the Week

Embolization of a...  
This 28-year-old man...  
flank pain 10 years...  
inferior vena cava

# Big business - risky business

Find a job Sign in Search ▾

ion | Sport | Culture | Lifestyle | More ▾

inking Money Markets Project Syndicate B2B

## AstraZeneca shares dive after failure in key lung cancer drug trial

Pharmaceuticals group suffers huge setback on 'Mystic' project as it reports that sales fell again in second quarter



▲ AstraZeneca shares have been under pressure in recent weeks amid speculation about its CEO. Photograph: Stefan Wermuth/Reuters

More than £10bn has been wiped off the market value of AstraZeneca after a major setback in a key lung cancer drug trial sent its shares plunging by more than 16%.

The  
**Guardian**

International editor

Advertisement

London Stock Exchange

Search for qu...

Home page Prices & markets News & events Statistics Products & services For traders & brokers

Home page > Prices & markets > Stocks > ASTRAZENECA



AZN ASTRAZENECA PLC ORD SHS \$0.25

SUMMARY | INTERACTIVE CHART | PRICES AND TRADES | FUNDAMENTALS | TECHNICAL ANALYSIS | NEWS




The Guardian, 27.7.17


# Andrelinjesbehandling ved lungekreft



# Førstelinjesbehandling ved lungekreft



JH. Schiller et al.: N Engl J Med 2002;346:92-8




Gandhi et al, NEJM 16.4.18

# Lungekreftplasser til vurdering i Beslutningsforum

- Osimertinib (etter progress på EGFR-hemmer)
- Dabrafenib/trametinib (BRAF-hemmer)
- Alektinib (ALK-hemmer)
- Ceritinib (ALK-hemmer)
- Etterhvert: pembrolizumab + kjemoterapi 1. linje, uavh. av PD-L1.

# Novel treatment algorithm, advanced NSCLC



Always consider clinical studies!



## PROGRAM

Nasjonalt tverrfaglig møte om lungekreft, 4. mai 2018  
**Forskningsbygget, Radiumhospitalet**

- 0900-0930: Registrering, frukt og kaffe
- 0930-0945: Velkommen, nytt fra NLCG  
*Odd Terje Brustugun, Drammen sykehus*
- 0945-1020: 1. Immunterapi ved småcellet lungekreft  
2. Sarkopeni-studien, de viktigste resultater  
*Bjørn Henning Grønberg, St Olavs hospital*
- 1020-1030: Diskusjon
- 1030-1050: Er luftforurensing en relevant årsak til lungekreft?  
*Jørn A. Holme, forskningssjef, Avd for luft og støy, Folkehelseinstituttet*
- 1050-1115: Pause
- 1115-1130: Aktuelle kliniske studier  
*Mette Sprauten, Radiumhospitalet/studiesykepleiere*
- 1130-1145: App som supplement i oppfølging ved lungekreft? Erfaringer fra gyn-kreft  
*Ingvild Vistad, Sørlandet Sykehus*
- 1145-1155: Diskusjon
- 1155-1245: Lunsj
- 1245-1325: Emosjonell utmattelse – hvordan kan det forebygges?  
*Tron Svagård, leder ved Villa Sana, Modum Bad*
- 1325-1335: Diskusjon
- 1335-1400: Pause
- 1400-1415: Registrering i kvalitetsregisteret – hvordan får vi det til?  
*Lars Fjellbirkeland, OUS Rikshospitalet*
- 1415-1430: Diskusjon
- 1430-1500: Oppsummering